SAB Biotherapeutics, Inc.
NCM: SABSLive Quote
📈 ZcoreAI Score
Our AI model analyzes SAB Biotherapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get SABS Z-Score →About SAB Biotherapeutics, Inc.
Healthcare
Biotechnology
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders and infectious diseases in the United States. Its lead product candidate is SAB-142, a potentially disease-modifying and redosable immunotherapy in clinical development for the treatment of autoimmune type 1 diabetes in Phase 2b clinical trials. The company was founded in 2014 and is headquartered in Miami Beach, Florida.
📊 Fundamental Analysis
SAB Biotherapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is 15.0%, which suggests room for improvement in capital utilization.
At a current price of $3.75, SABS currently sits at the 47th percentile of its 52-week range (Range: $1.23 - $6.60).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
✅
Beta (Risk)
Low Volatility
Key Financials
Market Cap
$263.53M
Trailing P/E
--
Forward P/E
-11.36
Beta (5Y)
0.61
52W High
$6.60
52W Low
$1.23
Avg Volume
569K
Day High
Day Low